Clinical Trials · NCT00630825
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 262
- Start date
- Apr 2008
- Locations
- 34 sites, United States, Puerto Rico
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus